Prevention of premature birth.
With six different groups of pharmacologic agents that potentially can inhibit undesirable uterine contractions, prevention of premature births should be increasingly successful. The rationale for the use of each of these agents and their advantages and disadvantages are discussed.
D000318:Adrenergic beta-Agonists / Q000494:pharmacology / Q000627:therapeutic use; D002118:Calcium / Q000037:antagonists & inhibitors; D055598:Chemical Phenomena; D002621:Chemistry; D016861:Cyclooxygenase Inhibitors; D003864:Depression, Chemical; D000431:Ethanol / Q000494:pharmacology / Q000627:therapeutic use; D005260:Female; D006801:Humans; D007213:Indomethacin / Q000494:pharmacology / Q000627:therapeutic use; D007752:Obstetric Labor, Premature / Q000517:prevention & control*; D010121:Oxytocin / Q000031:analogs & derivatives; D011247:Pregnancy; D011372:Progestins / Q000627:therapeutic use; D014590:Uterine Contraction / Q000187:drug effects
D000318:Adrenergic beta-Agonists; D016861:Cyclooxygenase Inhibitors; D011372:Progestins; D000431:Ethanol; D010121:Oxytocin; D002118:Calcium; D007213:Indomethacin